Clopidogrel News and Research

RSS

Clopidogrel is an oral antiplatelet agent (thienopyridine class) to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.

Trial tests effectiveness of two prospective stroke therapies over standard of care

Another goal of the study is to screen all participants for a mutation known to prevent clopidogrel, a prodrug, from being fully metabolized into its active form.

2 Sep 2021

ESO guidelines focus on early management of transient ischemic attack

The European Stroke Organization guidelines on management of Transient Ischemic Attack focus on issues specific to early TIA management.

16 Mar 2021

Study highlights the role of genetic testing in evaluation of in-stent thrombosis

In a new publication from Cardiovascular Innovations and Applications, Nathan Burke, Tawanna Charlton, Hussam Hawamdeh, and Ki Park from the University of Florida College of Medicine, Gainesville.

20 Nov 2020

Potent antiplatelet drug not superior to standard of care in reducing heart attack risk during angioplasty

The use of the more potent antiplatelet medication ticagrelor was not superior to clopidogrel in the reduction of the rate of heart attack or severe complications among people undergoing an elective procedure to open a blocked artery, according to late-breaking research presented today at the American Heart Association's Scientific Sessions 2020.

16 Nov 2020

Study shows best antiplatelet treatment after transcatheter aortic valve implantation

The POPular TAVI trial has challenged current guideline recommendations on antiplatelet treatment after transcatheter aortic valve implantation (TAVI) in patients not taking oral anticoagulation. The findings are presented in a Hot Line session today at ESC Congress 2020.

31 Aug 2020

Personalized genetic testing helps reduce adverse events following balloon angioplasty

An international, first-of-its-kind cardiology trial used personalized genetic testing to reduce by 34 per cent the number of serious adverse events following balloon angioplasty, a treatment for the most common form of heart disease.

26 Aug 2020

Precision medicine can determine the best drug treatment for severe heart disease

Is personalized medicine cost-effective? University of Alabama at Birmingham researcher Nita Limdi, Pharm.D., Ph.D., and colleagues across the United States have answered that question for one medical treatment.

15 May 2020

Study provides indications and techniques of lower extremity revascularization

Lower extremity artery disease is a leading cause of morbidity and mortality worldwide, affecting hundreds of millions of people.

7 May 2020

Clopidogrel added to aspirin and rvaroxaban shows no additional benefit for peripheral artery disease

The results of VOYAGER PAD found that people with peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing lower extremity revascularization--a procedure to treat blocked arteries in the leg--had a significant reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone.

31 Mar 2020

Clinical trial using genetic testing to guide antiplatelet therapy post-PCI falls short of stated goal

An international clinical trial that used genetic testing to guide which antiplatelet medication was given to patients following percutaneous coronary intervention (PCI) did not meet its stated goal for cutting in half the incidence of serious adverse cardiovascular events, such as heart attack and stroke, in the year following the procedure.

30 Mar 2020

Low-dose rivaroxaban reduces adverse heart events in symptomatic PAD post-intervention

People with symptomatic peripheral artery disease who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg (lower extremity revascularization) had a 15% reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

30 Mar 2020

Adding antiplatelet therapy to oral anticoagulants raises risk for TAVR patients with atrial fibrillation

Patients with atrial fibrillation who took oral anticoagulants alone after undergoing transcatheter aortic valve replacement had a lower rate of bleeding complications without an increased risk of clotting-related complications compared to patients who took antiplatelet medication in addition to oral anticoagulants, in a trial presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

29 Mar 2020

Partnership between medical specialties helps improve cardiovascular health

Starting in 2016, a two-year partnership between the North Carolina Chapter of the American College of Cardiology (NCACC) and the North Carolina Association of Free and Charitable Clinics (NCAFCC) provided free lipid lowering therapy and clopidogrel to patients at seven free clinics in North Carolina.

22 Jan 2020

Edoxaban-based dual therapy noninferior to standard treatment in atrial fibrillation post-stenting

Edoxaban in combination with a P2Y12 inhibitor is noninferior to standard triple therapy for preventing bleeding in patients with atrial fibrillation after coronary stenting.

4 Sep 2019

People with stroke can take common medicines without raising risk of another stroke

People who suffer a stroke caused by bleeding in the brain - known as brain hemorrhage - can take common medicines without raising their risk of another stroke, a major clinical trial has found.

23 May 2019

Scientists solve mystery surrounding mechanical forces that influence blood clotting

Researchers at the University of Sydney have used biomechanical engineering techniques to unlock the mystery surrounding the mechanical forces that influence blood clotting.

5 Apr 2019

Study shows ticagrelor is equally safe and effective as clopidogrel after heart attack

Patients given clot busters to treat a heart attack fared equally well if they were given the standard blood thinning medication clopidogrel versus the newer, more potent drug ticagrelor, according to research presented at the American College of Cardiology's 68thAnnual Scientific Session.

19 Mar 2019

Study indicates the benefits of stopping aspirin in heart attack patients

Patients who stopped taking aspirin three months after receiving a stent to open the heart's arteries but continued taking a P2Y12inhibitor—clopidogrel, prasugrel or ticagrelor—did not experience higher rates of death from any cause, heart attack or stroke after a year compared with those receiving standard therapy, according to research presented at the American College of Cardiology's 68thAnnual Scientific Session.

19 Mar 2019

Access to real-time genotype data influences prescriber behavior after PCI

Today, in a late-breaking featured clinical research session at the American College of Cardiology Scientific Sessions 2018, researchers from Penn Medicine present first-of-its-kind data on the impact of real-time CYP2C19 genotype results when prescribing antiplatelet drugs in the clinic.

13 Mar 2019

Combination treatment lowers risk of ischemic stroke recurrence

Stroke survivors taking a combination of the blood thinner cilostazol with aspirin or clopidogrel had a lower risk of ischemic stroke recurrence than those who received aspirin or clopidogrel alone, according to late breaking science presented at the American Stroke Association's International Stroke Conference 2019, a world premier meeting for researchers and clinicians dedicated to the science and treatment of cerebrovascular disease.

7 Feb 2019